Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viracta Therapeutics Inc (NQ: VIRX )

0.7201 -0.0599 (-7.68%)
Streaming Delayed Price Updated: 1:48 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viracta Therapeutics Inc

< Previous 1 2 Next >
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. 
Via Benzinga
Viracta Therapeutics: Q3 Earnings Insights
Via Benzinga
Expert Ratings for Viracta Therapeutics
Via Benzinga
VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023
VIRX stock results show that Viracta Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Why Porch Group Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Porch Group, Inc. (NASDAQ: PRCH) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Viracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next Stage
Via Benzinga
Analyst Ratings for Viracta Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 100 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 345 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 127 companies set new 52-week lows. 
Via Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Via Benzinga
Viracta Obtains Orphan Drug Status From European Commission For T-cell Lymphoma Candidate
The European Commission has granted an orphan drug designation (ODD) to Viracta’s (NASDAQ: VIRX) lead drug combination nanatinostat and valganciclovir (Nana-val) for the treatment of peripheral T-cell... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
  The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.